401 related articles for article (PubMed ID: 17175012)
21. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
22. The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma.
Pan J; Kong L; Lin S; Chen G; Chen Q; Lu JJ
Laryngoscope; 2008 Nov; 118(11):1970-5. PubMed ID: 18758376
[TBL] [Abstract][Full Text] [Related]
23. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Massard C; Voigt JJ; Laplanche A; Culine S; Lortholary A; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Fizazi K
Br J Cancer; 2007 Oct; 97(7):857-61. PubMed ID: 17876336
[TBL] [Abstract][Full Text] [Related]
24. Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays.
Kim JY; Lim SJ; Park K; Lee CM; Kim J
Gynecol Oncol; 2005 May; 97(2):337-41. PubMed ID: 15863127
[TBL] [Abstract][Full Text] [Related]
25. Oncogene alterations in endometrial carcinosarcomas.
Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
[TBL] [Abstract][Full Text] [Related]
26. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases.
Sato O; Wada T; Kawai A; Yamaguchi U; Makimoto A; Kokai Y; Yamashita T; Chuman H; Beppu Y; Tani Y; Hasegawa T
Cancer; 2005 May; 103(9):1881-90. PubMed ID: 15772959
[TBL] [Abstract][Full Text] [Related]
27. HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy.
Raspollini MR; Mecacci F; Paglierani M; Marchionni M; Taddei GL
Pathol Res Pract; 2005; 201(2):141-4. PubMed ID: 15901136
[TBL] [Abstract][Full Text] [Related]
28. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
Fjällskog ML; Lejonklou MH; Oberg KE; Eriksson BK; Janson ET
Clin Cancer Res; 2003 Apr; 9(4):1469-73. PubMed ID: 12684421
[TBL] [Abstract][Full Text] [Related]
29. [Uterine carcinosarcoma with chondroid differentiation--immuhistochemical examination].
Porjazova E; Zaprjanov Z; Batashki I; Markova D; Milchev N
Akush Ginekol (Sofiia); 2009; 48(2):26-8. PubMed ID: 20198774
[TBL] [Abstract][Full Text] [Related]
30. Effusion cytodiagnosis of carcinosarcoma derived from the female genital tract: immunohistochemical features of MMP-7 and Ki-67 and immunofluorescence double staining analyses of eight cases.
Ikeda K; Tate G; Suzuki T; Mitsuya T
Gynecol Oncol; 2005 May; 97(2):323-9. PubMed ID: 15863125
[TBL] [Abstract][Full Text] [Related]
31. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features.
Tsuda H; Tani Y; Weisenberger J; Kitada S; Hasegawa T; Murata T; Tamai S; Hirohashi S; Matsubara O; Natori T
Cancer Sci; 2005 Jun; 96(6):333-9. PubMed ID: 15958055
[TBL] [Abstract][Full Text] [Related]
32. Markers of apoptosis and angiogenesis indicate that carcinomatous components play an important role in the malignant behavior of uterine carcinosarcoma.
Yoshida Y; Kurokawa T; Fukuno N; Nishikawa Y; Kamitani N; Kotsuji F
Hum Pathol; 2000 Dec; 31(12):1448-54. PubMed ID: 11150369
[TBL] [Abstract][Full Text] [Related]
33. C-kit protein expression in uterine and ovarian mesenchymal tumours.
Erdogan G; Bassorgun CI; Pestereli HE; Simsek T; Karaveli S
APMIS; 2007 Mar; 115(3):204-9. PubMed ID: 17367465
[TBL] [Abstract][Full Text] [Related]
34. Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case.
Watanabe M; Shimizu K; Kato H; Imai H; Nakano H; Sugawa M; Shiraishi T
Gynecol Oncol; 2001 Sep; 82(3):563-7. PubMed ID: 11520156
[TBL] [Abstract][Full Text] [Related]
35. Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer.
Palmu S; Söderström KO; Quazi K; Isola J; Salminen E
Anticancer Res; 2002; 22(1A):411-4. PubMed ID: 12017324
[TBL] [Abstract][Full Text] [Related]
36. PDGFR-alpha as a potential therapeutic target in uterine sarcomas.
Adams SF; Hickson JA; Hutto JY; Montag AG; Lengyel E; Yamada SD
Gynecol Oncol; 2007 Mar; 104(3):524-8. PubMed ID: 17049587
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors.
Tawbi H; Thomas D; Lucas DR; Biermann JS; Schuetze SM; Hart AL; Chugh R; Baker LH
Oncologist; 2008 Apr; 13(4):459-66. PubMed ID: 18448562
[TBL] [Abstract][Full Text] [Related]
38. Expression profiles of carcinosarcoma of the uterine corpus-are these similar to carcinoma or sarcoma?
Chiyoda T; Tsuda H; Tanaka H; Kataoka F; Nomura H; Nishimura S; Takano M; Susumu N; Saya H; Aoki D
Genes Chromosomes Cancer; 2012 Mar; 51(3):229-39. PubMed ID: 22072501
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor expression in invasive thymoma.
Henley JD; Koukoulis GK; Loehrer PJ
J Cancer Res Clin Oncol; 2002 Mar; 128(3):167-70. PubMed ID: 11935304
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder.
Wang X; Zhang S; MacLennan GT; Eble JN; Lopez-Beltran A; Yang XJ; Pan CX; Zhou H; Montironi R; Cheng L
Clin Cancer Res; 2007 Feb; 13(3):953-7. PubMed ID: 17289890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
